- Home
- ADPT vs IOSP Comparison
ADPT vs IOSP Comparison
Compare ADPT & IOSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADPT
- IOSP
- Stock Information
- Founded
- ADPT 2009
- IOSP 1938
- Country
- ADPT United States
- IOSP United States
- Employees
- ADPT N/A
- IOSP N/A
- Industry
- ADPT Biotechnology: Biological Products (No Diagnostic Substances)
- IOSP Major Chemicals
- Sector
- ADPT Health Care
- IOSP Industrials
- Exchange
- ADPT Nasdaq
- IOSP Nasdaq
- Market Cap
- ADPT 2.0B
- IOSP 2.1B
- IPO Year
- ADPT 2019
- IOSP 1998
- Fundamental
- Price
- ADPT $14.40
- IOSP $78.15
- Analyst Decision
- ADPT Strong Buy
- IOSP Strong Buy
- Analyst Count
- ADPT 9
- IOSP 1
- Target Price
- ADPT $13.22
- IOSP $155.00
- AVG Volume (30 Days)
- ADPT 2.1M
- IOSP 247.6K
- Earning Date
- ADPT 11-06-2025
- IOSP 11-04-2025
- Dividend Yield
- ADPT N/A
- IOSP 2.15%
- EPS Growth
- ADPT N/A
- IOSP N/A
- EPS
- ADPT N/A
- IOSP 0.77
- Revenue
- ADPT $205,216,000.00
- IOSP $1,790,700,000.00
- Revenue This Year
- ADPT $32.76
- IOSP $0.25
- Revenue Next Year
- ADPT $15.81
- IOSP $7.46
- P/E Ratio
- ADPT N/A
- IOSP $101.28
- Revenue Growth
- ADPT 21.60
- IOSP N/A
- 52 Week Low
- ADPT $4.27
- IOSP $74.10
- 52 Week High
- ADPT $15.26
- IOSP $128.35
- Technical
- Relative Strength Index (RSI)
- ADPT 60.53
- IOSP 38.13
- Support Level
- ADPT $14.04
- IOSP $76.28
- Resistance Level
- ADPT $15.26
- IOSP $80.11
- Average True Range (ATR)
- ADPT 0.73
- IOSP 1.64
- MACD
- ADPT 0.05
- IOSP 0.05
- Stochastic Oscillator
- ADPT 69.09
- IOSP 28.31
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
About IOSP Innospec Inc.
Innospec Inc manufactures and sells a variety of chemicals and fuel additives. The firm organizes itself into three segments based on product type. The Fuel Specialties segment, which generates the majority of revenue, sells products used to improve fuel efficiency, boost engine performance, and reduce emissions for automobiles, boats, and airplanes. It also sells products used by oil field service providers in the extraction of oil and gas. The Performance Chemicals segment sells products to the personal-care industry. The Oilfield Services segment develops and markets products to prevent loss of mud.